$EYEG

Eyegate Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Other
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$1.97 ▲1.026%

Extented Hours

VOLUME

321,303

DAY RANGE

1.92 - 1.995

52 WEEK

1.44 - 8.18

Join Discuss about EYEG with like-minded investors

profile
@maletone #StockTraders.NET
recently

$EYEG going

128 Replies 15 👍 14 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

$eyeg $btbt nice so far

91 Replies 13 👍 6 🔥

profile
@Math #StockTraders.NET
recently

$XELA $OGEN $XBIO $TYME $OBSV $EYEG $TSLA

80 Replies 8 👍 11 🔥

profile
@Neptune5045 #StockTraders.NET
recently

lol $EYEG is so weak

84 Replies 10 👍 11 🔥

profile
@Neptune5045 #StockTraders.NET
recently

fully covered $EYEG

61 Replies 11 👍 14 🔥

profile
@TraderXx #StockTraders.NET
recently

$EYEG bailed, if it turns around later in the day, will reconsider

61 Replies 11 👍 13 🔥

profile
@Neptune5045 #StockTraders.NET
recently

covered most of $EYEG

46 Replies 12 👍 12 🔥

profile
@TraderXx #StockTraders.NET
recently

took long on $EYEG here at 6.70's

124 Replies 9 👍 8 🔥

profile
@TraderXx #StockTraders.NET
recently

hmm $EYEG is trading weird, with such a float...

127 Replies 7 👍 8 🔥

AL
@allstock13 #StockTraders.NET
recently

I dont have shares of $EYEG :-(

80 Replies 14 👍 6 🔥

profile
@TraderXx #StockTraders.NET
recently

$EYEG 9.50s, bring it

58 Replies 8 👍 7 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

$eyeg short

147 Replies 12 👍 6 🔥

profile
@TraderXx #StockTraders.NET
recently

$EYEG ohhhhh shorts in trouble

145 Replies 15 👍 6 🔥

Key Metrics

Market Cap

24.61 M

Beta

0.76

Avg. Volume

834.27 K

Shares Outstanding

12.62 M

Yield

0%

Public Float

0

Next Earnings Date

Next Dividend Date

Company Information

EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.

CEO: Stephen From

Website:

HQ: 271 Waverley Oaks Rd Ste 108 Waltham, 02452-8475 Massachusetts

Related News